U.S. markets close in 5 hours

Acceleron Pharma Inc. (XLRN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
123.69+1.50 (+1.23%)
As of 10:58AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close122.19
Open123.22
Bid123.43 x 1200
Ask123.65 x 800
Day's Range122.39 - 124.95
52 Week Range85.58 - 146.15
Volume101,522
Avg. Volume320,548
Market Cap7.508B
Beta (5Y Monthly)0.36
PE Ratio (TTM)N/A
EPS (TTM)-3.05
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est154.23
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia
    Business Wire

    Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia

    PRINCETON, N.J. & CAMBRIDGE, Mass., Jun 11, 2021--BMS & Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia

  • Acceleron to Host Virtual Research and Development (R&D) Day on June 22, 2021
    Business Wire

    Acceleron to Host Virtual Research and Development (R&D) Day on June 22, 2021

    Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it will host a Virtual R&D Day for analysts and investors on June 22, 2021. The virtual event will take place from 8:00 a.m. to approximately 11:00 a.m. EDT.

  • Ongoing Treatment With Acceleron's Sotatercept Continue To Show Benefit In PAH Patients
    Benzinga

    Ongoing Treatment With Acceleron's Sotatercept Continue To Show Benefit In PAH Patients

    Acceleron Pharma Inc (NASDAQ: XLRN) has announced interim results from the open-label extension of the PULSAR Phase 2 trial evaluating sotatercept in patients with pulmonary arterial hypertension (PAH). The data were presented at the American Thoracic Society 2021 International Conference. Investigators reported that patients experienced consistent or improved responses in multiple efficacy endpoints when treated with sotatercept for up to 48 weeks. Additionally, patients re-randomized to receive sotatercept on top of background therapies during weeks 24 to 48, after receiving placebo plus stable background therapy during the first 24 weeks of the trial, experienced clinical improvements consistent with those seen in the initial placebo-controlled treatment period. Sotatercept was generally well-tolerated. In the trial, serious treatment-emergent adverse events were reported in 28% of patients, and 9% of patients had adverse events that led to study discontinuation. See the ATS 2021 presentation here. Price Action: XLRN shares are down 0.55% at $123.9 during the market session on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaTreace Medical's Lapiplasty 3D Associated With Early Weightbearing After Foot Surgery, Interim Data ShowsNew Five-Year Data Shows Durable Efficacy Of AstraZeneca's Fasenra For Asthma Treatment© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.